Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Elan/Dura Shareholder Claims Rejected By Supreme Court

This article was originally published in The Pink Sheet Daily

Executive Summary

The shareholders failed to establish a causal connection between Dura’s alleged misrepresentations about the Spiros albuterol device in the late 1990s and any economic loss, the high court says in a unanimous opinion. Elan acquired Dura in 2000.

You may also be interested in...

High Court Justices Question Shareholders' "Loss" In Case Against Dura/Elan

In Dura v. Broudo oral arguments, several justices cite difficulty in connecting a February 1998 decline in the company's stock price, for which the shareholders seek compensation, with a disclosure nine months later that FDA deemed the company's Spiros albuterol device "not approvable."

Supreme Court To Hear Elan/Dura Shareholder Lawsuit On Securities Fraud Standards

Dura is asking the high court to consider whether shareholders must show a link between allegedly misleading statements and an actual drop in stock value, or just an inflated stock price on the date of purchase. The case stems from Dura’s 1997 statements about Ceclor CD and the Spiros albuterol device.

ACIP Shies Away From COVID-19 Vaccine Comparative Efficacy And Safety Evaluations

The CDC panel’s mandate is to make recommendations for each specific vaccine brought forward, not ‘comparing two, three or four vaccines, and coming up with specific recommendations for each one independent of the other,’ chairman Jose Romero says as ACIP recommends use of Janssen’s COVID-19 vaccine under EUA.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts